Treatment of Patients With Advanced Rectum Cancer With Capecitabine and Oxaliplatin Before, Under and After Radiation and With Adding Cetuximab to K-RAS Wild-type Patients

Copenhagen University Hospital at Herlev

Status and phase: Unknown; Phase 2

Conditions: Rectum Cancer

Treatments: Drug: cetuximab

Study type: Interventional

Funder types: Other

Identifiers

NCT00964457

GI0905

Details and patient eligibility

About

response rate to adding cetuximab, oxaliplatin and capecitabine to radiation for advanced rectum cancer

Full description

Dynamic MRI will be used to monitor the effect of the treatment and will be compared to pathologic results.

Enrollment: 60 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• advanced rectum cancer

Exclusion criteria

• prior radiation

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

60 participants in 2 patient groups

Capecitabine, oxaliplatin

Active Comparator group

Treatment:

Drug: cetuximab

capecitabine, oxaliplatin and cetuximab

Active Comparator group

Description:

capecitabine, oxaliplatin ane cetuximab

Treatment:

Drug: cetuximab